"5414X" is the RNS (Regulatory News Service) identifier for the released by Oxford Nanopore Technologies plc .
: £12.9 million (+27.4%), supported by synthetic biology.
: Introduced next-generation automated flow cell lines and strengthened quality assurance to ISO 13485 standards. "5414X" is the RNS (Regulatory News Service) identifier
The full text and detailed report of this "paper" (regulatory announcement) include the following key sections and financial highlights:
: 58.2%, slightly down from 58.8% in H1 2024 due to one-off inventory charges and currency headwinds, despite an underlying improvement of 525 basis points. Segment Growth : The full text and detailed report of this
: Established a strategic collaboration with Cepheid (a Danaher subsidiary) to develop automated infectious disease sequencing solutions. Leadership Update
Co-founder and CEO announced he will step down from his role and the board by the end of 2026. : Completed a programme resulting in an approximately
: Completed a programme resulting in an approximately 5% reduction in workforce to reallocate capital to growth areas.